<DOC>
	<DOCNO>NCT00303251</DOCNO>
	<brief_summary>This study open-label , dose-escalating study delineate safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) TKI258 . Pharmacokinetics pharmacodynamics perform subject . The eligible subject population consist subject diagnose locally advanced metastatic melanoma refractory standard therapy curative standard therapy exist .</brief_summary>
	<brief_title>Safety TKI258 Advanced/Metastatic Melanoma Subjects</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Confirmed diagnosis locally advance metastatic melanoma ( American Joint Committee Cancer [ AJCC ] stage IIIB , IIIC IV ) refractory standard therapy curative standard therapy exist . Measurable disease Must eighteen year age old Must meet baseline laboratory requirement ECOG performance status 0 1 Adults reproductive potential must agree use effective contraception sterile Concurrent therapy investigational agent Uncontrolled central nervous system metastasis Impaired cardiac function clinically significant cardiac disease Received chemotherapy , target therapy monoclonal antibody therapy ≤4 week biological therapy immunotherapy ( therapeutic diagnostic ) ≤2 week investigational agent ( therapeutic diagnostic ) ≤4 week prior start study drug recover side effect therapy Received hematopoietic colonystimulating factor ( e.g. , GCSF , GMCSF ) ≤ 2 week prior start study drug . Erythropoietin allow . Has undergone major surgery ≤ 2 week prior start study drug recover side effect surgery . Malabsorption syndrome uncontrolled gastrointestinal symptom nausea , diarrhea , vomit Pregnant breast feed woman History another primary malignancy currently clinically significant currently require active intervention . Chronic anticoagulation therapy full strength aspirin , Coumadin , heparin . History thromboembolic cerebrovascular event within last 12 month . History rectal bleeding , bloody vomit , spit blood within last 3 month . Known diagnosis HIV infection ( HIV test mandatory ) Use ketoconazole , erythromycin , carbamazepine , phenobarbital , phenytoin , rifampin , St. John 's wort quinidine prohibit . Other severe , acute , chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation studydrug administration may interfere interpretation study result , judgment investigator , make patient inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Locally Advanced Metastatic Melanoma</keyword>
</DOC>